Clinical Trials Logo
  1. Home
  2. Angiogenesis
  3. NCT05009407
  4. Details
NCT05009407 Clinical Trial

CD160 Expression in Corneal Vessels

Angiogenesis Clinical Trial

Official title:
CD160 Ans Corneal Graft: Expression in Corneal Vessels

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05009407
Other study ID # PO21062
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 21, 2021
Est. completion date July 21, 2024

Study information
Verified date April 2024
Source CHU de Reims
Contact Alexandre DENOYER
Phone 03 26 78 78 88
Email adenoyer@chu-reims.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis

Description:

After informed consent, patients enrolled for corneal graft surgery at the Robert Debré University Hospital, Reims, France, will be included. Routine general and eye examination including cornea photographs will be performed. During surgery, a quarter of patients' cornea and of donors' corneoscleral rim will be spared for immunohistochemistry analyzes.

Recruitment information / eligibility
Status Recruiting
Enrollment 20
Est. completion date July 21, 2024
Est. primary completion date July 21, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility inclusion criteria : - 18-year-old or more patients - enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France - considered able to give an informed written consent exclusion criteria : - none

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• Immunohistochemistry and clinical analyses on patients and corneas
Immunohistochemistry and clinical analyses on patients and corneas

Locations
Country Name City State
France Damien JOLLY Reims

Sponsors (1)
Lead Sponsor Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Micro-vascular densities neovascularization scores quantification of blood (anti-ERG+/anti-D2-40-) and lymphatic (anti-ERG+/anti-D2-40+) vascular structures ; Percentages of those vascular structures marked with anti-CD160 1 year
Secondary Percentages of those vascular structures marked with anti-CD160 and/or CD105 and/or aSMA 1 year
Secondary Evaluation of clinical blood vascular densities on photographs with help of ImageJ software 1 year
See also
  Status Clinical Trial Phase
Completed NCT06106932 - GnRH-a on Angiogenesis of Endometriosis N/A
Completed NCT04974983 - Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma
Recruiting NCT04566952 - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Phase 2
Recruiting NCT04145505 - Micrometastases and Angiogenesis in Colon Cancer. Prognostic Value of VEGF.
Active, not recruiting NCT02396888 - Effects of Local Insulin on Wound Angiogenesis Phase 3
Completed NCT03705247 - The Role of Bleeding at Implant Placement
Recruiting NCT04556071 - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Phase 2
Completed NCT04609332 - Endothelial Damage and Angiogenesis Biomarkers During COVID-19
Completed NCT03162588 - Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya Phase 1/Phase 2
Recruiting NCT04772001 - Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer N/A
Not yet recruiting NCT04807166 - Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Phase 2
Completed NCT04310280 - Effects of Local Insulin on Varicose Ulcers for Wound Healing Phase 3
Completed NCT04670107 - The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy Phase 1/Phase 2
Completed NCT00727948 - The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy Early Phase 1
Completed NCT02603406 - Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits Phase 2
Recruiting NCT03991871 - HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study N/A
Completed NCT00744536 - Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS Phase 2
Completed NCT00728598 - Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis N/A
Active, not recruiting NCT04851054 - Postoperative VEGF and Recurrence After Colon Cancer Surgery
Not yet recruiting NCT02865304 - The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients Phase 3